Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUMATRIPTAN; NAPROXEN SODIUM vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Acute treatment of migraine attacks with or without aura in adults
Mild to moderate pain,Fever
Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Sumatriptan: terminal half-life approximately 2.5 hours (range 1.5–4.6 hours); clinically, short half-life limits duration of action. Naproxen sodium: terminal half-life approximately 12–17 hours (mean 14 hours); long half-life allows twice-daily dosing and sustained analgesic effect.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Sumatriptan is primarily metabolized by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Sumatriptan: renal excretion of unchanged drug and metabolites (primarily indole acetic acid analogue) accounts for approximately 60% of elimination; fecal/biliary excretion accounts for about 40%. Naproxen sodium: renal excretion of unchanged drug (approximately 60%) and glucuronide conjugates (about 40%); less than 5% is excreted fecally.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Sumatriptan: protein binding approximately 14–21% (low binding). Naproxen sodium: protein binding >99% (highly bound to albumin).
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Sumatriptan: Vd approximately 2.2 L/kg (indicates extensive tissue distribution). Naproxen sodium: Vd approximately 0.16 L/kg (low Vd, consistent with high protein binding and limited tissue distribution).
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Sumatriptan: oral bioavailability approximately 15% (due to first-pass metabolism); subcutaneous injection 96%; intranasal approximately 17%. Naproxen sodium: oral bioavailability >95% (well absorbed).
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Contraindicated if GFR <30 m L/min; for GFR 30-50 m L/min, caution with naproxen component; no specific dose adjustment recommended for sumatriptan.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Contraindicated in severe hepatic impairment (Child-Pugh class C); sumatriptan maximum dose 50 mg per dose in moderate impairment (Child-Pugh class B); naproxen sodium avoid in severe impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for patients <12 years; for adolescents 12-17 years, single dose of sumatriptan 85 mg / naproxen sodium 500 mg (as adult formulation) per clinical judgment, not to exceed 1 dose in 24 hours.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Avoid use in elderly due to increased risk of cardiovascular events, gastrointestinal bleeding, and renal impairment; if necessary, use lowest effective dose for shortest duration.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Cardiovascular and gastrointestinal risks: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. NSAIDs also increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Sumatriptan is contraindicated in patients with history of coronary artery disease or risk factors. Do not use within 24 hours of another 5-HT1 agonist or ergotamine-containing medication.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Cardiovascular events: Myocardial ischemia, infarction, arrhythmia, and death reported with sumatriptan. NSAIDs increase risk of serious cardiovascular thrombotic events.,Gastrointestinal effects: NSAIDs increase risk of GI bleeding, ulceration, and perforation.,Excessive use: Medication overuse headache may occur.,Serotonin syndrome: Risk with concurrent use of serotonergic drugs.,Renal effects: NSAIDs can cause renal toxicity.,Hypertension: Sumatriptan may increase blood pressure.,Anaphylactic reactions: Serious allergic reactions including anaphylaxis reported with sumatriptan.,Hepatic effects: NSAIDs may cause liver enzyme elevations.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
History of coronary artery disease (CAD) or coronary artery vasospasm,Wolff-Parkinson-White syndrome or other cardiac accessory pathway disorders,History of stroke or transient ischemic attack,Peripheral vascular disease,Ischemic bowel disease,Uncontrolled hypertension,Within 24 hours of treatment with another 5-HT1 agonist (e.g., triptans) or ergotamine-containing medications,Concomitant use or within 2 weeks of MAO-A inhibitor,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,In the setting of coronary artery bypass graft (CABG) surgery,Third trimester of pregnancy
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid alcohol (may exacerbate migraine and increase GI irritation). Limit caffeine intake (can trigger migraine). No specific food restrictions, but maintain hydration.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction and reduced placental perfusion. Naproxen: First trimester – potential increased risk of cardiac defects; second trimester – generally safe with caution; third trimester – contraindicated due to risk of premature ductus arteriosus closure, oligohydramnios, and fetal renal dysfunction.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Sumatriptan: Excreted in breast milk with estimated relative infant dose of 3.5% of maternal weight-adjusted dose; M/P ratio not well defined. Naproxen: Excreted in breast milk with M/P ratio approximately 0.01; relative infant dose <1% of maternal dose. Both considered compatible with breastfeeding with monitoring for infant adverse effects.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No specific dose adjustments recommended for sumatriptan in pregnancy; however, limited data suggest no significant pharmacokinetic changes. Naproxen: Clearance may increase in later pregnancy; dose adjustments not well studied. Avoid naproxen in third trimester.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Sumatriptan/naproxen sodium is contraindicated within 24 hours of another triptan or ergotamine. Naproxen dose is fixed; avoid additional NSAIDs to prevent GI bleeding or renal impairment. Use with caution in patients with cardiovascular risk factors. Onset of action is 10-30 minutes; advise against driving if dizziness occurs.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take at the first sign of migraine; do not exceed one tablet in 24 hours.,Do not take within 24 hours of other triptans or ergotamine-containing drugs.,Avoid alcohol during migraine attack as it may worsen symptoms.,Report chest tightness, palpitations, or shortness of breath immediately.,Do not drive or operate machinery if feeling dizzy or drowsy.,Inform healthcare provider of all medications, especially blood thinners or antidepressants.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"Naproxen and meloxicam are both nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) enzymes, leading to decreased synthesis of prostaglandins, prostacyclin, and thromboxanes. Concomitant use increases the risk of dose-dependent adverse effects, particularly gastrointestinal ulceration, bleeding, and perforation, as well as renal impairment, due to additive inhibition of protective prostaglandins in the gut and kidney. Clinically, this combination may result in acute kidney injury, anemia from occult gastrointestinal bleeding, or life-threatening perforation, especially in elderly patients or those with pre-existing renal disease or peptic ulcer history."
"Bevantolol, a beta-1 selective adrenergic receptor antagonist, reduces cardiac output and suppresses renin release, thereby lowering blood pressure. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins and enhanced sodium and water retention. The net effect is an attenuation of bevantolol's antihypertensive efficacy, potentially resulting in elevated blood pressure and reduced cardiovascular protection."
"Betaxolol, a beta-1 selective adrenergic receptor antagonist, may reduce the antihypertensive efficacy of naproxen, a nonsteroidal anti-inflammatory drug (NSAID). Naproxen inhibits cyclooxygenase (COX) enzymes, leading to decreased synthesis of vasodilatory prostaglandins (e.g., prostacyclin) in the renal and vascular endothelium. This can result in sodium and fluid retention, increased systemic vascular resistance, and blunting of the blood pressure-lowering effects of beta-blockers like betaxolol, potentially compromising hypertension control."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUMATRIPTAN; NAPROXEN SODIUM vs ACEPHEN, answered by our medical review team.
SUMATRIPTAN; NAPROXEN SODIUM is a 5-HT1 Agonist that works by Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUMATRIPTAN; NAPROXEN SODIUM and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUMATRIPTAN; NAPROXEN SODIUM is: Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUMATRIPTAN; NAPROXEN SODIUM and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUMATRIPTAN; NAPROXEN SODIUM is classified as Category D/X. Sumatriptan: Limited data; no increased risk of major congenital malformations observed in cohort studies. Avoid use in third trimester due to potential uterine vasoconstriction an. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.